Genmab — Marts 2021
-
Epco has the lead over glofi on safety and subcu, it might of course change if Roche a subcu version for glofi, but so far there is not clear proof of that.
-
develope a subcu version
-
Det er nok snarere Gen1042 https://clinicaltrials.gov/ct2/show/NCT04083599?term=Gen1042&draw=2&rank=1 i tarmkræft
-
-
Begge har fremragende data, men en lille fordel til epco ville lune, specielt da glofi vil være først på markedet, dog kun som IV. Epco først som SC
-
Mosunetuzumab har vel ikke samme effekt som epco. Det var i hvert fald Martin Hutchings konklusion på CMD.
-
Glofi er mere effektful end mosu, og derved er det glofi som epco først og fremmest skal konkurrere imod...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind